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 Retinal artery occlusion (RAO) is a vision-threatening
disease, primarily affecting patients older than 60 years. In-
sufficient blood flow in the retinal arteries leading to infarc-
tion of the affected retinal tissue is caused by several different
mechanisms including embolization, hemorrhage under an ath-
erosclerotic plaque, and thrombus formation [1,2]. Among oth-
ers, atherosclerosis has been identified as a major risk factor
for RAO [1].
Atherosclerosis is a chronic low-grade inflammatory dis-
ease [3]. Both pro- and anti-inflammatory cytokines have been
shown to modulate atherogenesis [4,5]. Interleukin 10 (IL-
10), a pleiotropic, anti-inflammatory cytokine, is synthesized
by several cell types including macrophages and T lympho-
cytes [6]. It exerts antiatherogenic effects by suppressing the
production of both pro-inflammatory cytokines and matrix
metalloproteinases, and by downregulating the expression of
tissue factor (TF) and adhesion molecules [6-12]. Further evi-
dence for the role of
IL-10 in atherogenesis comes from animal experiments,
demonstrating that increased IL-10 expression leads to reduced
formation of early and advanced atherosclerotic lesions,
whereas IL-10 deficiency is associated with enhanced athero-
genesis [10,13-19].
In humans, IL-10 production is to a large extent geneti-
cally determined [20,21]. The IL10 gene is located at chro-
mosome 1q31-q32. A [TCATA] haplotype formed by poly-
morphisms at position -3575, -2763, -1082, -819 and -592 in
the promoter region of the IL10 gene has been associated with
increased IL-10 expression [22]. Due to linkage disequilib-
rium, the presence of this haplotype can be fully determined
by the analysis of the IL10 -592C>A gene polymorphism
(rs1800872). The [TCATA] haplotype is identified by the pres-
ence of the IL10 -592A-allele, while the -592C-allele indi-
cates its absence [22,23].
The purpose of the present study was to investigate a hy-
pothesized association between the haplotype-tagging IL10 -
592C>A polymorphism and the presence of RAO.
METHODS
 The present retrospective case-control study consisted of 194
patients with RAO and 257 control subjects. All participants,
who were seen at the local department of ophthalmology be-
tween October 1998 and July 2006, gave written informed
consent prior to being enrolled. The study was conducted in
accordance with the guidelines of the National Gene Technol-
ogy Act and the local Ethics Committee.
All participants underwent an ophthalmologic examina-
tion that included visual acuity tests as well as, slit-lamp and
fundus examinations. The diagnosis of RAO was made by
fundus examination in which superficial retinal whitening was
found in the distribution of the affected retinal artery. Since
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549second eye involvement occurred in two patients, 93 eyes were
diagnosed with central retinal artery occlusion (CRAO), while
branch retinal artery occlusion (BRAO) was present in 103
eyes. Patients with RAO due to giant cell arteritis or other
types of vasculitis were considered ineligible for participa-
tion.
The control group was comprised of patients who had
been seen at the local department of ophthalmology for rea-
sons other than RAO. Those with a history of retinal vascular
occlusion or vasculitis were deemed ineligible.
Arterial hypertension was defined by systolic blood pres-
sure greater or equal to 140 mm Hg and/or diastolic blood
pressure greater or equal to 90 mm Hg, and/or the current in-
take of antihypertensive drugs. Subjects were classified as dia-
betics, if they were being treated for insulin- or non-insulin-
dependent diabetes. Hypercholesterolemia was defined by the
intake of lipid-lowering drugs and/or a fasting plasma choles-
terol level >200 mg/dL. Patients were further classified as
current or non-smokers.
Genotype determination:  Genomic DNA was isolated
from peripheral blood lymphocytes by standard methods and
stored at -20 °C. Genotypes of the IL10 -592C>A polymor-
phism were determined by a 5'-exonuclease assay (TaqMan)
using a procedure described by Langsenlehner, et al. [24].
Primer and probe sets were designed and manufactured using
Applied Biosystems “Assay-by-Design” custom service
(Applera, Vienna, Austria). The polymerase chain reaction
(PCR) was performed in a Primus 96 plus thermal cycler
(MWG Biotech AG, Germany) using a total volume of 5 µl
containing 2.5 µl SuperHot-Master-Mix (Bioron GmbH,
Ludwigshafen, Germany), 0.125 µl 40x Assay-by-Design mix
(Applera), 0.375 µl H2O and 2 µl DNA. Reactions were over-
laid with 15 µl mineral oil. Cycling parameters were as fol-
lows: 1 min 94 °C for primary denaturation, followed by 40
cycles of 15 s 92 °C and 1 min 60 °C. Fluorescence was mea-
sured in a lambda Fluoro 320 Plus plate reader (MWG Biotech
AG) using excitation/emission filters of 485/530 nm for FAM-
labeled probes (IL10 -592A-allele) and 530/572 nm for VIC-
labeled probes (IL10 -592C-allele). The data were exported
into Excel format and depicted and analyzed as a scatter plot.
Statistics:  SPSS for Windows (release 11.0.1; SPSS, Inc)
was used for statistical analyses. Continuous variables were
analyzed by Student’s t-test and are presented as means±SD.
Categorial variables are presented as percentages and were
compared by chi-square test. Odds ratios and 95% confidence
intervals (CI) were determined by logistic regression analy-
sis. The criterion for statistical significance was p less than or
equal to 0.05.
RESULTS
 Clinical characteristics of patients and control subjects are
shown in Table 1. Prevalences of arterial hypertension and
current-smoking status were significantly higher in patients
than among controls.
Table 2 presents the genotype distribution of the IL10 -
592C>A polymorphism in patients and control subjects. Car-
riers of the IL10 -592A-allele (AA+CA genotypes) were found
significantly more often in the control group than among pa-
tients with RAO (p=0.008). Carriage of the IL10 -592A-allele
yielded an odds ratio of 0.60 (95% CI: 0.41-0.87; p=0.008)
for RAO, and remained significant after adjusting for age, sex,
arterial hypertension, hypercholesterolemia, smoking status
and diabetes mellitus (odds ratio: 0.65; 95% CI: 0.44-0.97;
p=0.036).
In a subgroup analysis, prevalences of the CC, CA and
AA genotypes did not significantly differ between eyes with
CRAO (61.3%, 36.6%, and 2.2%, respectively) and those with
BRAO (67.0%, 28.2%, and 4.9%, respectively).
No deviation from the genotype distribution predicted by
the Hardy-Weinberg equilibrium was observed in either pa-
tients or controls, and allelic frequencies in the control group
were similar to those previously reported by other investiga-
tors [24,25].
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TABLE 1. CLINICAL CHARACTERISTICS OF RETINAL ARTERY OCCLUSION
PATIENTS AND CONTROLS
Clinical characteristics of retinal artery occlusion (RAO) patients and
controls. Prevalences of arterial hypertension and current smoking
status were significantly higher in patients than among control sub-
jects. Numbers are given as n (%); asterisk (*) indicates p<0.001.
TABLE 2. DISTRIBUTION OF IL10 -592C>A GENOTYPES IN RETINAL
ARTERY OCCLUSION PATIENTS AND CONTROLS
Distribution of IL10 -592C>A genotypes in retinal artery (RAO)
patients and controls. Carriers of the IL10 -592A-allele (AA+CA
genotypes) were found significantly more often in the control group
than among patients with retinal artery occlusion. Numbers for geno-
types are given as n (%). Data were compared by chi square test
asterisk (*; AA+CA) versus CC.
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 The production of IL-10 has been shown to be under tight
genetic control with heritability estimates up to 74% [20]. The
IL10 [TCATA] haplotype formed by five polymorphisms in
the promoter region of the IL10 gene has been associated with
increased IL-10 synthesis [22]. Due to linkage disequilibrium,
the absence or presence of the IL10 [TCATA] haplotype can
be unequivocally determined by analysis of the IL10 -592C>A
polymorphism [22,23].
To the best of our knowledge, the present study is the
first to investigate the haplotype-tagging IL10 -592C>A poly-
morphism in patients with RAO. Genotyping was performed
in 194 patients and 257 control subjects. Carriers of the -592A-
allele (AA+CA), which indicates the presence of the high IL-
10-producing [TCATA] haplotype, were found significantly
more often in controls than among patients with RAO. A sub-
group analysis revealed a similar genotype distribution be-
tween eyes with BRAO and CRAO, indicating that this poly-
morphism is a risk factor for both types of RAO. In a logistic
regression analysis, after adjusting for age, sex, arterial hy-
pertension, hypercholesterolemia, diabetes mellitus, and smok-
ing habits the presence of the IL10 -592A-allele was associ-
ated with an odds ratio of 0.65 for RAO, suggesting a protec-
tive effect against RAO.
Besides arterial hypertension and cigarette smoking,
which are known to initiate or promote atherogenesis [3], ath-
erosclerosis itself plays a major role in the pathogenesis of
RAO [1,2]. Since increased IL-10 expression has been shown
to reduce the formation of atherosclerotic lesions [10,13-19],
our finding that the IL10 [TCATA] haplotype exerts a protec-
tive effect against RAO seems biologically plausible. Among
other mechanisms, IL-10 mediates antiatherogenic pathways
by suppressing the production of pro-inflammatory cytokines
such as interleukin 1 beta (IL-1β), interleukin 12 (IL-12), tu-
mor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6)
[6-8]. Interestingly, an IL-6 promoter polymorphism has re-
cently been reported as a novel risk factor for RAO [26]. This
further suggests that genetic influences on both pro- and anti-
inflammatory cytokines contribute to the risk of RAO.
As a potential limitation of our study, IL-10 plasma con-
centrations were not determined. The purpose of our study,
however, was to investigate the role of a haplotype-tagging
genetic polymorphism, since in contrast to plasma cytokine
concentrations, genetic variants do not change over life-time.
Beside the [TCATA] haplotype, other polymorphisms in the
IL10 gene might also influence IL-10 expression and thereby
affect RAO risk. Further studies focusing on these gene vari-
ants may provide additional insight in the role of IL10 in RAO.
In conclusion, our study demonstrates that the IL10
[TCATA] haplotype, indicated by the presence of the IL10 -
592A-allele, may be associated with a protective effect against
RAO. Yet, large prospective studies are warranted to confirm
the contribution of these IL10 promoter gene polymorphisms
to the risk of RAO.
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